Stryker Co. (NYSE:SYK) Shares Sold by Key Financial Inc

Key Financial Inc trimmed its stake in Stryker Co. (NYSE:SYK - Free Report) by 55.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 870 shares of the medical technology company's stock after selling 1,069 shares during the period. Key Financial Inc's holdings in Stryker were worth $313,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Dunhill Financial LLC raised its stake in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after acquiring an additional 37 shares during the period. Darwin Wealth Management LLC purchased a new stake in shares of Stryker in the 3rd quarter valued at approximately $36,000. Activest Wealth Management purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $36,000. Crews Bank & Trust purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $39,000. Finally, Hara Capital LLC purchased a new stake in shares of Stryker in the 3rd quarter valued at approximately $42,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on SYK. StockNews.com downgraded shares of Stryker from a "buy" rating to a "hold" rating in a research note on Thursday, January 30th. Evercore ISI upped their target price on shares of Stryker from $380.00 to $384.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 target price on shares of Stryker in a research note on Wednesday, January 29th. Citigroup upped their target price on shares of Stryker from $411.00 to $450.00 and gave the stock a "buy" rating in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus upped their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $420.68.

Stryker Stock Performance

NYSE:SYK traded down $3.82 during trading hours on Friday, reaching $382.59. 1,268,413 shares of the company's stock were exchanged, compared to its average volume of 1,388,856. The firm has a market capitalization of $145.99 billion, a price-to-earnings ratio of 49.30, a P/E/G ratio of 2.93 and a beta of 0.96. The company has a 50-day moving average of $378.07 and a 200 day moving average of $368.67. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the company posted $3.46 earnings per share. Research analysts anticipate that Stryker Co. will post 13.49 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.